FIG 1.

Total antibody titers targeting the RBD and neutralization of live SARS-CoV-2. (a) Anti-RBD IgG titers of vaccine (BNT162b2) recipients (n = 21) and COVID-19 patients (n = 19) were depicted. No significant difference in the level of total anti-RBD IgG titers was observed. (b) The half-maximal neutralization titers (NT50s) were remarkably lower in the vaccinated group than those in patients. (c) The anti-RBD IgG/NT50 ratio was plotted for both groups. Black horizontal bars indicate geometric mean with geometric standard deviation. Red dots denote the subset of samples chosen for the microarray analysis. For detailed information on subjects, see Table S1.